A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Ironwood Pharmaceuticals, Inc. · Irritable Bowel Syndrome Characterized by Constipation
Phase 3
Completed
614
2020-12
Industry sponsor intelligence
Ironwood Pharmaceuticals, Inc.Clinical Pipeline.
Lead-sponsor view of Ironwood Pharmaceuticals, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 11
- Recruiting
- 0
- Active
- 0
- Completed
- 10
- Results posted
- 9
- Avg enrollment
- 601
Pipeline overview
Programs by phase and activity.
Velocity
Ironwood Pharmaceuticals, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
11phase labels
Early Phase 10
Phase 10
Phase 25
Phase 35
Phase 41
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Linaclotide → | 11 | 0 | 5 | 5 | 1 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Ironwood Pharmaceuticals, Inc. · Irritable Bowel Syndrome With Constipation
Phase 2
Completed
759
2020-04
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Ironwood Pharmaceuticals, Inc. · Irritable Bowel Syndrome With Constipation · Chronic Constipation
Phase 3
Completed
1,743
2018-02
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Ironwood Pharmaceuticals, Inc. · Chronic Idiopathic Constipation
Phase 3
Completed
1,223
2017-06
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Ironwood Pharmaceuticals, Inc. · Irritable Bowel Syndrome With Constipation
Phase 3
Completed
805
2013-11
Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation
Ironwood Pharmaceuticals, Inc. · Chronic Constipation
Phase 2
Completed
310
2013-03
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Ironwood Pharmaceuticals, Inc. · Irritable Bowel Syndrome With Constipation
Phase 2
Completed
420
2013-02
Trial of Linaclotide in Patients With Chronic Constipation
Ironwood Pharmaceuticals, Inc. · Chronic Constipation
Phase 3
Completed
643
2013-01
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
Ironwood Pharmaceuticals, Inc. · Constipation
Phase 2
Completed
40
2009-03
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
Ironwood Pharmaceuticals, Inc. · Irritable Bowel Syndrome
Phase 2
Completed
36
2006-10
Search sponsor records
All Ironwood Pharmaceuticals, Inc. studies.
This page groups studies where Ironwood Pharmaceuticals, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
11 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT02837783A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)Dec 6, 2021NCT03573908A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Dec 1, 2020NCT02559206Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Apr 24, 2020NCT00730171An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationFeb 19, 2018NCT02291679Trial of Linaclotide in Patients With Chronic Idiopathic ConstipationJun 15, 2017NCT00938717Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Nov 5, 2013NCT00402337Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic ConstipationMar 5, 2013NCT00460811Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Feb 4, 2013NCT00730015Trial of Linaclotide in Patients With Chronic ConstipationJan 30, 2013NCT00306748Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic ConstipationMar 24, 2009